Karyopharm Therapeutics Announces Nine Presentations on its Selective Inhibitors of Nuclear Export (SINE) Compounds and PAK4 Inhibitors at the American Association of Cancer Research (AACR) Meeting
[GlobeNewswire] – NATICK, Mass. — Karyopharm Therapeutics Inc. , a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets … moreView todays social media effects on KPTIView the latest stocks trending across Twitter. Click to view dashboardSee who Karyopharm is hiring next, click here to view […]
